TIMING OF COST-EFFECTIVENESS ANALYSIS IN BREAST CANCER: AN ANALYSIS OF PEER-REVIEWED LITERATURE

• Published in: Value in health Vol. 20; no. 5; p. A106
• Main Authors: van den Broek, R, Lam, NH, Lukose, A, Yoruk, B
• Format: Journal Article
• Language: English
• Published: Lawrenceville Elsevier Science Ltd 01.05.2017
• Subjects: Analysis; Breast cancer; Cost analysis; Decision makers; Drug therapy; Drugs; ErbB-2 protein; Health care; Literature reviews; Monoclonal antibodies; Peer review; Regulatory agencies; Reviews; Sponsorship; Targeted cancer therapy; Timing; Trastuzumab; Websites; United States > US; Europe

OBJECTIVES: To review the time frame between drug approval dates and their cost-effectiveness analysis publications in breast cancer treatment from a US and European perspective. METHODS: A literature analysis was performed using EMBASE to identify cost-effectiveness analyses published from January...